Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Long-term health care interruptions among HIV-positive patients in Uganda.

Mills EJ, Funk A, Kanters S, Kawuma E, Cooper C, Mukasa B, Odit M, Karamagi Y, Mwehire D, Nachega J, Yaya S, Featherstone A, Ford N.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):e23-7. doi: 10.1097/QAI.0b013e31828a3fb8.

PMID:
23406979
2.

Treatment outcomes from the largest antiretroviral treatment program in Myanmar (Burma): a cohort analysis of retention after scale-up.

Sabapathy K, Ford N, Chan KN, Kyaw MK, Elema R, Smithuis F, Floyd S.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e53-62. doi: 10.1097/QAI.0b013e31824d5689.

PMID:
22334069
3.

Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.

Alvarez-Uria G, Naik PK, Pakam R, Midde M.

Glob Health Action. 2013 Sep 12;6:21682. doi: 10.3402/gha.v6i0.21682.

4.

Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.

Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11. doi: 10.1097/QAI.0b013e3181b843f0.

5.

The social and clinical characteristics of patients on antiretroviral therapy who are 'lost to follow-up' in KwaZulu-Natal, South Africa: a prospective study.

Peltzer K, Ramlagan S, Khan MS, Gaede B.

SAHARA J. 2011;8(4):179-86. doi: 10.1080/17290376.2011.9725002.

PMID:
23236959
6.

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR.

AIDS. 2007 May 11;21(8):965-71.

PMID:
17457090
7.

Antiretroviral treatment for HIV in rural Uganda: two-year treatment outcomes of a prospective health centre/community-based and hospital-based cohort.

Kipp W, Konde-Lule J, Saunders LD, Alibhai A, Houston S, Rubaale T, Senthilselvan A, Okech-Ojony J.

PLoS One. 2012;7(7):e40902. doi: 10.1371/journal.pone.0040902. Epub 2012 Jul 17.

8.

Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults.

Nachega JB, Mutamba B, Basangwa D, Nguyen H, Dowdy DW, Mills EJ, Katabira E, Nakimuli-Mpungu E.

Trop Med Int Health. 2013 Jan;18(1):53-7. doi: 10.1111/tmi.12019. Epub 2012 Nov 8.

9.

Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up.

Knobel H, Urbina O, González A, Sorlí ML, Montero M, Carmona A, Guelar A.

HIV Med. 2009 Jul;10(6):364-9. doi: 10.1111/j.1468-1293.2009.00696.x. Epub 2009 Mar 11.

10.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
11.

Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses.

Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, Downing R, Mermin J, Weidle PJ.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):578-83.

PMID:
15793369
12.

The prognostic value of baseline CD4(+) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting.

Mills EJ, Bakanda C, Birungi J, Yaya S, Ford N; TASO-CAN Writing Group.

AIDS. 2012 Jul 17;26(11):1425-9. doi: 10.1097/QAD.0b013e328354bf43.

PMID:
22526520
13.

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

PMID:
22293548
14.

Patients' demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals.

Odafe S, Idoko O, Badru T, Aiyenigba B, Suzuki C, Khamofu H, Onyekwena O, Okechukwu E, Torpey K, Chabikuli ON.

J Int AIDS Soc. 2012 Sep 18;15(2):17424. doi: 10.7448/IAS.15.2.17424.

15.

Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa.

Greig J, O'Brien DP, Ford N, Spelman T, Sabapathy K, Shanks L.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):e92-8. doi: 10.1097/QAI.0b013e31824206c7.

PMID:
22134144
16.

Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda.

Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, Graziano FM.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1371-6. doi: 10.5588/ijtld.11.0589. Epub 2012 Aug 3.

PMID:
22863182
17.

Lack of pre-antiretroviral care and competition from traditional healers, crucial risk factors for very late initiation of antiretroviral therapy for HIV--a case-control study from eastern Uganda.

Muhamadi L, Tumwesigye NM, Kadobera D, Marrone G, Wabwire-Mangen F, Pariyo G, Peterson S, Ekström AM.

Pan Afr Med J. 2011;8:40. Epub 2011 Apr 7.

18.

Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia.

Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M, Auld A, Agolory S, Mukadi YD, Colebunders R, Bangsberg DR, van Praag E, Torpey K, Williams S, Kaplan J, Zee A, Denison J.

Trop Med Int Health. 2014 Dec;19(12):1397-410. doi: 10.1111/tmi.12386. Epub 2014 Sep 17.

19.

Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda.

Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, Bernheimer I, Musinguzi N, Yiannoutsos CT, Martin JN.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e64-71. doi: 10.1097/QAI.0b013e31828af5a6.

20.

Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda.

Sendagire I, Cobelens F, Kambugu A, Konde-Lule J, van der Loeff MS.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e33-9. doi: 10.1097/QAI.0b013e318265aad7.

PMID:
22820807
Items per page

Supplemental Content

Write to the Help Desk